Amphastar Pharmaceuticals, Inc.
Health
Performance
6.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Amphastar Pharmaceuticals, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.01.2026
On shaky ground. Struggling to find a clear direction.
07.01.2026
Slight bounce. Could be noise – or a comeback brewing.
01.01.2026
Stability slipping. Financial grip’s not as firm as it was.
15.11.2025
Off life support. Still risky, but slightly less scary.

Amphastar Pharmaceuticals, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Amphastar Pharmaceuticals, Inc. do? Business model and key facts

Get the full picture of Amphastar Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.

Amphastar Pharmaceuticals, Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 2028

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

shop
Company facts
Yongfeng Zhang
CEO
2028
Employees worldwide
shop
Performance
-29.26%
Last 12 months
39.41%
Last 5 years
shop
Growth
$731,97M
Revenue year
$159,52M
Net income
shop
Valuation
$1,21B
Market Cap
11.27
Price/Earnings Ratio

Stocks related to Amphastar Pharmaceuticals, Inc.

Selected based on industry alignment and relative market positioning.

EVO
Evotec SE
3.66
+0.55%
5.8
Sell
Buy
Evotec SE
COLL
Collegium Pharmaceutical, Inc.
45.32
-1.09%
6.3
Sell
Buy
Collegium Pharmaceutical, Inc.
HROW
Harrow Health, Inc.
42.98
-1.94%
7.2
Sell
Buy
Harrow Health, Inc.
CRON
Cronos Group Inc.
2.71
+0.74%
5.3
Sell
Buy
Cronos Group Inc.
PCRX
Pacira BioSciences, Inc.
19.85
-3.17%
5.9
Sell
Buy
Pacira BioSciences, Inc.

Amphastar Pharmaceuticals, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.